Atezolizumab for Pretreated Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonia: Final Analysis of Phase II AMBITIOUS Study

BACKGROUND: Interstitial pneumonia (IP) is a poor prognostic comorbidity in patients with non-small cell lung cancer (NSCLC) and is also a risk factor for pneumonitis. The TORG1936/AMBITIOUS trial, the first known phase II study of atezolizumab in patients with NSCLC with comorbid IP, was terminated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Kato, Terufumi, Kenmotsu, Hirotsugu, Ogura, Takashi, Sato, Yuki, Hino, Aoi, Harada, Toshiyuki, Kubota, Kaoru, Tokito, Takaaki, Okamoto, Isamu, Furuya, Naoki, Yokoyama, Toshihide, Hosokawa, Shinobu, Iwasawa, Tae, Kasajima, Rika, Miyagi, Yohei, Misumi, Toshihiro, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438913/
https://www.ncbi.nlm.nih.gov/pubmed/35759340
http://dx.doi.org/10.1093/oncolo/oyac118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438913/
https://www.ncbi.nlm.nih.gov/pubmed/35759340
http://dx.doi.org/10.1093/oncolo/oyac118

Ejemplares similares